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Induction of cross-reactive cellular and humoral responses to the HIV-1 envelope (env) glycoprotein was examined after DNA
immunization of BALB/c mice with gp14089.6-derived constructs exhibiting partial or complete deletions of the V1, V2, and V3 domains. It
was demonstrated that specific modification of the V3 loop (mV3) in combination with the V2-modified (mV2) or V1/V2-deleted (DV1/V2)
region elicited increased levels of cross-reactive CD8+ T cell responses. Mice immunized with the mV2/mV3 or DV1/V2/mV3 gp14089.6
plasmid DNAwere greater than 50-fold more resistant to challenge with recombinant vaccinia virus (rVV) expressing heterologous env gene
products than animals immunized with the wild-type (WT) counterpart. Sera from mV2/mV3- and DV1/V2/mV3-immunized mice exhibited
the highest cross-neutralizing activity and displayed intermediate antibody avidity values which were further enhanced by challenge with
rVVexpressing the homologous gp160 glycoprotein. In contrast, complete deletion of the variable regions had little or no effect on the cross-
reactive antibody responses. The results of these experiments indicate that the breadth of antibody responses to the HIV-1 env glycoprotein
may not be increased by removal of the variable domains. Instead, partial deletions within these regions may redirect specific responses
toward conserved epitopes and facilitate approaches for boosting cross-reactive cellular and antibody responses to the env glycoprotein.
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1999; Reitter et al., 1998; Wyatt et al., 1998). However, toIntroduction
The current challenge for the design of effective HIV-1
vaccines is to develop immunization strategies to elicit both
stronger and broader immunity against diverse viral species
(Chakrabarti et al., 2002; Schulke et al., 2002). The enve-
lope (env) glycoprotein is an important component of an
efficacious vaccine for AIDS because gp120 is the major
viral surface glycoprotein and a key mediator of the entry
process (Binley et al., 2000; Kwong et al., 2000; Moore and
Binley, 1998; Moore and Sodroski, 1996; Parren et al.,0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.10.009
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E-mail address: danuta.kozbor@roswellpark.org (D. Kozbor).persist as a chronic infection, HIV-1 has evolved ways to
escape from cytotoxic T lymphocyte (CTL) recognition and
to limit the generation of neutralizing antibodies. This
includes mutations arising within regions of the viral ge-
nome encoding immunodominant epitopes that contribute to
viral spread and the inability of anti-HIV-1 immunity to
prevent the onset of AIDS (Goulder et al., 1999). Addition-
ally, there is extensive shielding of conserved regions by
carbohydrates (Reitter et al., 1998) and hiding of the
coreceptor-binding site by variable loops of gp120 until
the CD4 interaction occurs, thereby minimizing the time and
space available for the antibody to intervene against this
stage of the fusion process (Kwong et al., 1998; Moore and
Binley, 1998). Because the overall structure of gp120 must
be at least partially conserved for the protein to function in
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binding sites may provide a target for structural modifica-
tions to induce broadly neutralizing antibodies.
Although mechanisms responsible for induction of cross-
protective antibody responses to the HIV-1 env glycoprotein
remain to be elucidated, several lines of evidence indicate
that exposure of certain neutralizing epitopes participating
in the env-CD4 and -coreceptor binding can be increased by
structural modification of the variable domains of gp120
(Barnett et al., 2001; Cao et al., 1997; Malenbaum et al.,
2000; Stamatatos and Cheng-Mayer, 1998). Changes in the
gp120 V2 loop or V1/V2 stem region that are responsible
for both CD4-independent entry into cells and gp120
binding to CCR5 in the absence of CD4 (Kolchinsky et
al., 1999, 2001) can alter immunogenicity of the single or
double mutant. For example, deletion of the V1 and V2
loops from the env glycoprotein of the HIV-1HXBc2 was
shown to increase susceptibility of the virus to neutralization
by anti-V3 and certain CD4-induced monoclonal antibodies
(Cao et al., 1997). Deletion of the central region of the V2
loop in gp120 of the HIV-1SF162DV2 isolate enhanced
induction of cross-neutralizing antibodies by altering the
immunogenicity of the V3 and V1 loops and rendering the
C5 region immunogenic (Barnett et al., 2001; Srivastava et
al., 2003). Deletion of the V1/V2 variable loop also leads to
a significant reduction of the carbohydrate content (Reitter
et al., 1998) that modulates the conformation of the V1/V2
stem-loop and affects the exposure of conserved, discontin-
uous structures on the HIV-1 gp120 glycoprotein (Wyatt et
al., 1995). Studies in rhesus monkeys revealed that simian
immunodeficiency virus mac239 variants lacking specific
N-linked carbohydrate attachment sites within and around
the V1 and V2 regions of gp120 were more sensitive to
antibody-mediated neutralization and better elicitors of
neutralizing antibody responses (Reitter et al., 1998).
The third hypervariable loop is another domain of
gp120 that modulates immunogenicity of the env glyco-
protein (Trkola et al., 1996). A number of studies based
on the construction of chimeric env glycoproteins of X4
and R5 strains have demonstrated that the V3 loop is the
primary determinant of tropism and coreceptor usage
(Hung et al., 1999; Hwang et al., 1991), although other
domains of gp120 are also involved (Basmaciogullari et
al., 2002; Ross and Cullen, 1998). It has been reported
that V3 loop-derived peptides can inhibit viral entry into
target cells or syncytium formation between cells express-
ing the env glycoproteins of HIV-1 and cells that co-
express CD4 and CCR5 or CXCR4 in a coreceptor-
specific manner (Verrier et al., 1999). Recent studies have
demonstrated that human monoclonal antibodies (mAbs)
which recognize epitopes at the crown of the V3 loop
derived from the HIV-1JR-CSF isolate showed cross-clade
binding to native, intact virions of clades A, B, C, D, and
F (Gorny et al., 2002). Additionally, the N-terminal V3
loop glycan was found to block access to the binding site
for CD4 and modulated the chemokine receptor bindingsite of phenotypically diverse clade A and clade B isolates
(Malenbaum et al., 2000). Because the majority of pri-
mary HIV-1 isolates reveals good exposure of the V3
region on the surface of intact virions (Nyambi et al.,
2000a, 2000b), it has been suggested that antibodies
which react with conformation-sensitive epitopes of the
V3 loop may have potent cross-neutralizing activities
(Park et al., 2000).
While ‘‘sterilizing’’ immunity mediated by broadly neu-
tralizing antibody responses remains the ultimate goal for
prophylactic HIV-1 vaccines, env-specific CTL responses
may represent an important component of therapeutic vac-
cines. For example, the clearance of HIV-1 from plasma
during the primary infection occurs before the appearance of
neutralizing antibodies in newly infected individuals (Moore
et al., 1994). In many studies, vaccinated macaques were
able to efficiently control a virus challenge in the absence of
detectable neutralizing antibodies, particularly those animals
that were immunized with live, attenuated virus vaccines
(Bogers et al., 1995; Cho et al., 2001; Dunn et al., 1997).
Additional studies in pigtailed macaques demonstrated that
animals immunized with a mixture of HIV-1 env glycopro-
teins exhibited lower levels of plasma virus than monkeys in
the control group despite the absence of any detectable
neutralizing antibody, suggesting induction of superior cel-
lular responses by the polyvalent vaccine (Cho et al., 2001).
Our previous studies have demonstrated that immunization
of the HLA-A2/Kb transgenic mice with the DV3 env
vaccine enhanced CD8+ T-cell responses to conserved
epitopes of gp160 and broaden cross-reactive CTL
responses (Kiszka et al., 2002). However, the ability of
the DV3 gp14089.6 mutant to induce cross-reactive neutral-
izing antibody responses has not been examined. Therefore,
it was of interest to analyze neutralization activities in DV3-
immunized mice and compare them with responses induced
by gp14089.6-derived constructs exhibiting partial or com-
plete deletions of the V1, V2, and V3 domains. This head-
to-head analysis of cellular and humoral responses demon-
strated that partial deletion of the V3 domain in combination
with V2 or V1/V2 region modifications increased the
breadth and potency of cellular, and to a lesser degree,
protective antibody responses.Results
Variable domain-modified env vaccines
To analyze the effect of specific modifications within the
variable region of the env glycoprotein on the repertoire of
cellular and humoral responses, we have generated DNA
vaccines with partial or complete deletions of the V1, V2,
and V3 domains on the background of gp140 of the HIV-
189.6 isolate. Several reasons underlay this choice: (i) the
HIV-189.6 virus is a primary, dual tropic virus (Doranz et al.,
1996); (ii) it is a molecularly cloned virus with a well-
Fig. 1. Schematic representation of the variable domain-modified HIV-189.6 gp140 mutants. The amino acid sequences of V1 and V2 domains of the WT env
glycoprotein and the mV2 and DV1/V2 mutants are shown in the upper panel. The lower panel depicts the amino acid sequence of the V3 loop of the WT env
glycoprotein and the mV3 and DV3 mutants. In all mutants, the GAG sequence replaced the deleted residues. The 303T/A substitution in the mV3 domain is
indicated by asterisk. The numbering of amino acids is based on the HxBc2 sequence available from the HIV Sequence Database.
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previously expressed the gp140 protein from HIV-189.6 and
analyzed its immunogenicity in mice (Kiszka et al., 2002).Fig. 2. Immunoprecipitation of WT and domain-modified HIV-189.6 gp140 glycop
the WT or the variable domain-modified env glycoproteins were radiolabeled w
proteins from cell lysates were immunoprecipitated with a mixture of sera from H
protein A-Sepharose CL-4B.To generate the variable region-modified gp14089.6
mutants with deletion of the V1 and V2 domains (DV1/
V2), residues 121 to 203 were replaced with a 3-aa sequenceroteins. The 293T cells transiently transfected with plasmid DNA encoding
ith [35S]methionine/cysteine and lysed in Nonident P-40 buffer. The env
IV-1-infected individuals followed by polyclonal rabbit anti-human Ig and
J. Gzyl et al. / Virology 318 (2004) 493–506496(GAG) as indicated in Fig. 1 (upper panel). Similarly, the
GAG sequence replaced the deleted residues 298 to 329 in
the DV3 mutant (Fig. 1, lower panel). We have also
prepared an additional set of V2 and V3 domain-modified
gp14089.6 constructs wherein the variable loops were only
partially deleted (Fig. 1). In the V2 loop-modified mutant
(mV2), the residues 162 to 191 were replaced with GAG,
leaving the RLISC sequence in V2 as it represents a part of
the CTL epitope RLISCNTSV with the A2-binding motif
(Korber et al., 1999). The V3 loop-modified construct
(mV3) retained the N-terminal 23-aa fragment from cysteine
296 to arginine 320. This segment contained the GPGR
sequence recognized by the broadly neutralizing 447-52D
human mAb (Conley et al., 1994) and the RRLSIGP
sequence, in the N-terminal side of the V3 loop, that shares
antigenic feature recognized by human mAbs with intra-
and interclade cross-reactivity (Gorny et al., 1997). The
mV3 loop also contained several CTL epitopes with multi-Fig. 3. Immunofluoresce staining and flow cytometry analysis of the full-length a
transfectants. The expression of the env glycoproteins was analyzed 48 h after tran
by the FITC-conjugated F(abV)2 portion of goat anti-human Ig. Cells were analyze
stained only with the secondary antibody. Continuous and dotted lines indicate trple HLA-binding motifs (Korber et al., 1999), and had the
N-linked glycan at residue 303 eliminated by the NNT to
NNA amino acid replacement. This N-linked glycan was
shown to block access to the binding site for CD4 and
modulated the chemokine receptor binding site of pheno-
typically diverse clade A and clade B isolates (Malenbaum
et al., 2000).
The variable region deletions were introduced in the
HIV-1 gp14089.6 construct together or separately, and cloned
in frame with the human tissue plasminogen activator (tPA)
signal sequence for expression in the pNGVL-7 plasmid as
DNA vaccines. The expressions of the WT and domain-
modified gp140 proteins were analyzed by immunoprecip-
itation of transiently transfected 293 cells. The env glyco-
proteins were immunoprecipitated from cellular lysates of
[35S]methionine/cysteine-labeled transfectants with a mix-
ture of sera from HIV-1-infected individuals and resolved by
SDS-PAGE. Because the HIV-189.6 gp140 was originallynd variable domain-modified HIV-189.6 gp140 proteins expressed in 293T
sfection by intracellular staining with 2F5 and 2G12 human mAbs followed
d by flow cytometry on FACScan. The light gray areas denote transfectants
ansfectants stained with 2F5 and 2G12 mAbs, respectively.
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the furin cleavage motif was replaced with a hexameric
Leu–Arg motif (Binley et al., 2000), the full-length and
domain-modified env glycoproteins were immunoprecipi-
tated as single bands (Fig. 2). The mutants could be
distinguished based on differences in the molecular weight
due to complete or partial deletions of the variable regions.
Variations in the expression levels between the WT and the
env mutants were less than 30%, suggesting that the
expression of the gp140 mutants was not largely altered
by the variable loop modifications. Furthermore, immunos-
taining of intracellularly expressed env mutants in transient-
ly transfected 293 cells with broadly neutralizing antibodies
revealed that the gp140 mutants retained native antigenic
determinants similar to the unmodified env protein (Fig. 3).
The broadly neutralizing mAbs 2G12 and 2F5 used for
staining recognize a carbohydrate-dependent epitope located
on the gp120 outer domain and the NEQELLSLWN epitope
near the C-terminal end of the gp41 ectodomain, respec-
tively (Parker et al., 2001; Trkola et al., 1996).
Breadth of cellular responses induced by immunization with
the WT and domain-modified mutants of HIV-189.6 gp140
protein
In the first set of experiments, we compared the ability of
domain-modified env vaccines to induce cross-reactive
CD8+ T cell responses. Groups of BALB/c mice (n = 5)
were immunized intramuscularly (i.m.) with DNA vaccines
expressing the complete or domain-modified gp14089.6
glycoproteins. Three weeks after the last immunization,
frequencies of IFN-g-secreting splenocytes were analyzed
by ELISPOT assay against P815 (H-2d) target cells infected
with recombinant vaccinia virus (rVV) expressing homolo-Fig. 4. Induction of cross-reactive cellular responses by DNA immunization with W
The numbers of IFN-g-secreting CD8+ T cells in splenocyte cultures established f
assay with P815 cells infected with vPE16, vV1, and vBD3. Control cells were i
meansF SD of at least three independent experiments. The frequencies of IFN-g-s
by plotting the number of spots versus the number of effector cells.gous (vBD3) or heterologous (vPE16 or vV1) env gene
products. Cells infected with vSC8 virus expressing h-
galactosidase served as negative control. This analysis
permitted detection of env-specific CD8+ T cells because
the P815 mastocytoma cell line expresses only MHC class I
molecules (Gherardi and Esteban, 1999).
As shown in Fig. 4, immunization with WT and domain-
modified env mutants induced comparable frequencies of
env-specific IFN-g-secreting CD8+ splenocytes against the
homologous gp160 gene products. However, the profile of
CD8+ T cell responses directed to heterologous gp160
varied among mice immunized with different env vaccines.
For example, CD8+ T cells derived from mice immunized
with the WT gp14089.6 construct exhibited a rather restricted
pattern of reactivity, in which the heterologous responses
were at approximately 35% (vPE16) and 15% (vV1) of
those directed to the homologous env gene products. Im-
munization with the mV2 or DV1/V2 mutant had no effect
on the profile of cross-reactive IFN-g responses in cultures
stimulated with vPE16 or vV1-infected target cells. On the
other hand, the DV3 and mV3 env-induced cellular immu-
nity showed a broader pattern of reactivity responding to
vPE16- and vV1-infected target cells with approximately
40% higher efficiencies than responses elicited by the WT
env vaccine. Among the double deletants, the highest levels
of cross-reactive responses were induced with the mV2/
mV3 and DV1/V2/mV3 gp14089.6 vaccines. In mice immu-
nized with the mV2/mV3 gp14089.6 mutant, the responses to
vPE16- and vV1-infected cells represented approximately
75% and 60% of those directed to target cells expressing the
homologous env gene products, respectively. They were
also significantly higher than the heterologous responses in
animals immunized with the WT gp14089.6 vaccine (P =
0.003 and P = 0.0002, respectively). A similar profile ofT and variable domain-modified HIV-189.6 gp140 mutants in BALB/c mice.
rom mice immunized with the env vaccines were determined by ELISPOT
nfected with vSC8 expressing h-galactosidase. Results are presented as the
ecreting cells were determined by regression analysis from a curve generated
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whose cross-reactive CD8+ T cell activities directed to
vPE16- and vV1-infected targets were 2- and 3-fold higher
compared to those elicited by the unmodified vaccine (P =
0.02 and P = 0.009, respectively). The latter responses
represented 70% and 45% of IFN-g-secreting CD8+ sple-
nocytes directed to vBD3-infected cells, respectively.
Protection against challenge with rVV expressing
homologous and heterologous env glycoproteins
The significance of WT and domain-modified env vac-
cine-induced cellular responses was further examined in
protective studies against challenge with vPE16, vV1, and
vBD3 as surrogates for HIV-1 (Belyakov et al., 1998).
BALB/c mice immunized with the full-length or variable
loop-modified mutants of the gp14089.6-derived DNA con-
structs were challenged on day 28 by intraperitoneal (i.p.)
injection with 5  106 PFU of vPE16, vV1, or vBD3 as
described (Kiszka et al., 2002). To determine whether any
protection induced by the vaccines was env-specific, addi-
tional groups of immunized and control mice were chal-
lenged with vSC8 virus expressing h-galactosidase.
Because the vaccinia virus replicates most efficiently in
ovaries (Belyakov et al., 1998), ovaries were removed 5
days after the challenge and tested for vaccinia titer on a
monolayer of HuTK 143B cell line.
As shown in Table 1, the vaccinia titers in ovaries of
mice immunized with the full-length env or the domain-
modified mutants and challenged with vBD3 were approx-
imately 3 log10 lower than in vSC8-challenged animals. The
protection levels against the homologous challenge with
vBD3 were comparable in animals immunized with the
unmodified or domain-modified vaccines. Consistent with
the profile of CD8+ T cell responses, immunization with the
WT env gene products elicited approximately 10- and 100-Table 1
Env vaccine-induced protection against challenge with rVV expressing homologo
Envelope Challengea
vaccine
vSC8 vBD3
Virus titerb
(log10/ovaries)
Virus titerb
(log10/ovaries)
Protectionc
(Dlog10)
WT 9.1 F 0.8 6.0 F 0.4 3.1
mV2 9.2 F 0.6 6.3 F 0.6 2.9
DV1/V2 9.0 F 0.8 6.2 F 0.5 2.8
mV3 8.7 F 0.8 5.6 F 0.4 3.1
DV3 9.1 F 0.5 6.1 F 0.4 3.0
mV2/mV3 8.8 F 0.8 5.3 F 0.2 3.5
mV2/DV3 9.2 F 0.6 5.6 F 0.2 3.6
DV1/V2/mV3 8.8 F 0.7 5.4 F 0.3 3.4
DV1/V2/V3 8.6 F 0.7 5.8 F 0.2 2.8
a On day 28 after immunization with the WT or domain-modified gp14089.6 DNA
vV1, vBD3, or vSC8. Five days later, mice were sacrificed, ovaries were remove
serial 10-fold dilutions on human HuTK 143B cells, staining with crystal violet
b The rVV titers are presented as the mean log10 F SD of PFU per ovaries of fo
c Protection is reduction of vBD3, vPE16, or vV1 titers (Dlog10 PFU) in ovaries cfold lower protection levels against heterologous challenge
with vPE16 and vV1, respectively. A similar level of
protection was detected in mice immunized with the mV2
or DV1/V2 deletant. Animals immunized with the DV3 or
mV3 mutant and challenged with the heterologous vPE16
and vV1 viruses had approximately 10-fold lower viral titers
in ovaries than WT env-vaccinated mice. The highest level
of protection against the heterologous challenge was
detected in mV2/mV3- and DV1/V2/mV3-immunized mice.
In these animals, resistance to heterologous challenge with
vPE16 and vV1 was similar and approximately 50-fold
higher compared with mice immunized with WT
gp14089.6 (P < 0.01). There was no significant difference
between vSC8 titers in control mice and those immunized
with the WT env or any of the domain-modified mutants,
indicating that the protection elicited by the mV2/mV3 and
DV1/V2/mV3 gp14089.6 mutants could not be mediated by
nonspecific inflammatory responses.
Development of env-specific antibodies in mice immunized
with the domain-modified gp14089.6 vaccines
The full-length and domain-modified HIV-189.6 gp140-
derived immunogens induced antibodies capable of binding
to the homologous env glycoprotein expressed on the
surface of vBD3-infected cells (Table 2). Although varia-
tions in the antibody titers were measured throughout the
immunization schedule, no statistically significant differ-
ences were recorded among groups of mice vaccinated with
different env constructs. The endpoint binding antibody
titers in animals immunized with the unmodified or the
modified env vaccines were in the range of 2  103 at the
end of the vaccination schedule. These results suggest that,
based on the assay used here to determine antibody titers,
the domain-modified gp140 vaccines were as effective as
the unmodified env in eliciting antibody responses even ifus and heterologous gp160 of primary HIV-1 isolates
vPE16 vV1
Virus titerb
(log10/ovaries)
Protectionc
(Dlog10)
Virus titerb
(log10/ovaries)
Protectionc
(Dlog10)
7.4 F 0.5 1.7 8.0 F 0.6 1.1
7.2 F 0.7 2.0 7.6 F 0.5 1.6
7.1 F 0.7 1.9 7.7 F 0.6 1.3
6.6 F 0.4 2.1 6.8 F 0.5 1.9
6.8 F 0.2 2.3 7.0 F 0.4 2.1
5.7 F 0.3 3.1 5.9 F 0.2 2.9
6.2 F 0.3 3.0 6.4 F 0.3 2.8
5.9 F 0.2 2.9 6.1 F 0.4 2.7
6.3 F 0.2 2.3 6.5 F 0.4 2.1
vaccines, BALB/c mice were challenged i.p. with 5  106 PFU of vPE16,
d, homogenized, sonicated, and assayed for vaccinia virus titers by plating
, and counting plaques at each dilution.
ur mice per group.
ompared with the value for the control group challenged with vSC8 virus.
Table 2
Env-specific antibody responses and neutralization activities induced by the domain-modified HIV-189.6 gp140 vaccines
Domain-modified Antibody titer to the homologous envelope Specific neutralization (% inhibition F SD)b
HIV-189.6 gp140 vaccines glycoprotein (endpoint titer F SD)
a
HIV-189.6 HIV-1SF162
WT 2100 F 461 36 F 16 17 F 8
mV2 2933 F 562 70 F 19 49 F 15
DV1/V2 1600 F 800 48 F 44 28 F 26
mV3 2000 F 565 28 F 11 ND
DV3 1867 F 661 24 F 9 26 F 22
mV2/mV3 2400 F 800 91 F 19 86 F 9
mV2/DV3 2240 F 661 81 F 10 67 F 11
DV1/V2/mV3 1800 F 546 95 F 13 88 F 14
DV1/V2/V3 3133 F 1194 67 F 34 60 F 16
a The env-specific antibody responses to native viral env glycoprotein expressed in vBD3-infected 293 cells were analyzed in sera of mice immunized with the
WT or the variable domain-modified gp14089.6 vaccine using the ELISA assay. Sample dilutions were considered positive if the optical density recorded for
that dilution was at least 2-fold higher than the optical density recorded for a naive sample at the same dilution (Staats et al., 1996). Results are from three
independent experiments.
b The neutralizing antibody responses induced by the WT and variable domain-modified env vaccines were examined using the homologous HIV-189.6 isolate
and CEMx174 cells, or the heterologous HIV-1SF162 virus and PHA-stimulated PBMC as target cells. Neutralizing activity was evaluated at 1:20 dilution,
taking into consideration the nonspecific neutralization recorded with sera collected from animals vaccinated with the DNA vector alone. Results represent
means F SD from three independent experiments.
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V1/V2 and 31 amino acids from the V3 region.
Next, we investigated the ability of unmodified and
domain-modified HIV-189.6 gp140 vaccines to generate
neutralizing antibodies to the functional env glycoprotein
on the HIV-1 virus. In the initial set of experiments, the
neutralizing assay was performed using the homologous
HIV-189.6 isolate and the susceptible CEMx174 cells as a
target. Analysis of p24-antigen levels in culture supernatants
of CEMx174 cells infected with HIV-189.6 in the presence or
absence of the immune sera revealed that immunization with
the unmodified gp14089.6 vaccine was not very effective in
inducing neutralizing antibodies (Table 2). The neutralizing
activity of the WT gp14089.6-induced antibody responses
measured at a serum dilution of 1:20 revealed 36 F 16%
inhibition of infection. A similar profile of neutralizing
activity was observed with sera from animals immunized
with the single mV3 or DV3 deletant. A trend toward higher
neutralization levels was recorded in sera collected from
animals vaccinated with the mV2 mutant, and the neutral-
izing activities of the serum antibodies were further aug-
mented in mV2/mV3- and DV1/V2mV3-immunized mice
(P < 0.02).
To examine whether domain-modified gp140 vaccines
were effective in eliciting cross-reactive neutralizing anti-
body responses, we tested the HIV-1SF162 isolate whose
susceptibility to neutralization by sera collected from animals
immunized with the DV2 gp140SF162 mutant had previously
been examined (Barnett et al., 2001; Srivastava et al., 2003).
At a 1:20 serum dilution, the sensitivity of the HIV-1SF162
virus to neutralization by sera obtained frommice immunized
with the unmodified gp14089.6 vaccine was at least 2-fold
lower than that detected using the homologous HIV-189.6
virus (17 F 8% inhibition of infection, Table 2). At this
dilution, a mixture of sera from HIV-1-infected individuals,
used as a positive control in the assay, inhibited the infectionby >95%. Removal of the entire V1/V2 region or the V3 loop
did not augment the neutralizing responses. The antibody-
neutralizing potency was 2–3-fold enhanced in sera derived
from animals immunized with the mV2, mV2/DV3, or DV1/
V2/V3mutant (P < 0.03). The highest, approximately 5-fold,
increases in susceptibility of the HIV-1SF162 virus to neutral-
ization were elicited by mV2/mV3 and DV1/V2/mV3
gp14089.6 vaccines (P = 0.0006 and P = 0.002, respectively),
indicating that specific modifications of the variable loops
might be capable of redirecting antibody responses toward
conserved epitopes on the env glycoprotein.
Env-specific antibody avidity
Previous studies with attenuated SIV vaccines in rhesus
macaques demonstrated that the establishment of long-term
protective immunity was associated with maturation of
antibody responses (Cole et al., 1997; Montelaro et al.,
1998). These results prompted us to evaluate the nature of
anamnestic responses to rVV challenge in mice immunized
with domain-modified mutants that elicited the highest
cross-reactive neutralizing antibody responses after DNA
priming. Because variations in priming specificity by the
variant env immunogens could be reflected in differences in
the protective immune responses to the viral challenge, we
measured the association between env-specific antibody
avidity and neutralizing activities in sera of mice immunized
with the WT, mV2/mV3, or DV1/V2/mV3 vaccine after
challenge with vBD3 virus expressing homologous env
gene products. Mice immunized with the env-specific
DNA vaccines and challenged with vSC8 virus expressing
h-galactoside served as controls. The antibody avidity was
determined by measuring the relative stability of the native
env antigen–antibody complexes to an 8 M urea wash in
concanavalin A (ConA) ELISA assay as described (Cole et
al., 1997).
Table 3
Env-specific antibody responses after rVV challenge in mice immunized
with the WT, mV2/mV3, or DV1/V2/mV3 gp14089.6 vaccine
Envelope Challengea Avidity Specific neutralizationc
vaccine indexb (%)
HIV-189.6 HIV-1SF162
50% 90% 50% 90%
WT ND 25    
WT vBD3 37 +   
mV2/mV3 vSC8 43 + + + 
mV2/mV3 vBD3 56 + + + +
DV1/V2/mV3 vSC8 34 + + + 
DV1/V2/mV3 vBD3 49 + + + 
a BALB/c mice were immunized with plasmid DNA expressing the WT,
mV2/mV3, or DV1/V2/mV3 mutant of gp14089.6 and challenged i.p. with
5  106 PFU of vBD3 or vSC8 3 weeks after DNA vaccine. The env-
specific antibody responses to the native env glycoprotein were analyzed in
the ConA ELISA with or without an 8 M urea wash. ND, not determined.
b The avidity index was determined by measuring the relative stability of
the native viral env antigen–antibody complexes to an 8-M urea wash in
ConA ELISA, and values were calculated by using the equation (urea-
washed wells/PBS-washed wells)  100. The avidity index values x z
50%, 50% > x > 30%, and x V 30% have been defined high, intermediate,
and low avidity, respectively. Results represent average values from three
independent experiments.
c Neutralizing activity was calculated at 1:20 dilution, taking into
consideration the nonspecific neutralization recorded with sera collected
from animals vaccinated with the DNA vector alone. , 50% specific
neutralization was not recorded; +, 50% or 90% specific neutralization was
recorded. Results are from three independent neutralization experiments.
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antibody avidity values in mice immunized with the env-
specific DNA constructs showed approximately 30%
increases after challenge with vBD3 vaccinia virus com-
pared to responses in vSC8-challenged mice. In the latter
group of mice, the antibody avidity index varied between
25% and 43% with the lowest and highest values detected in
animals immunized with the WT and mV2/mV3 vaccines,
respectively. The antibody responses progressed from low to
intermediate or to high avidity in vBD3-challenged mice at
11 days postinfection. The increases in antibody avidity
after vBD3 challenge were also associated with small
enhancement of neutralization activities against the HIV-
189.6 and HIV-1SF162 isolates in animals immunized with the
WT and mV2/mV3 vaccines, respectively (Table 3). How-
ever, this association was not observed in DV1/V2/mV3-
vaccinated mice whose sera displayed similar neutralizing
activities after challenge with vBD3 or vSC8 virus.Discussion
Potent neutralizing antibody responses that prevent pri-
mary infection or reduce the viral load at the site of HIV-1
entry remain the ultimate goal for prophylactic AIDS
vaccines. However, the same vaccines should also induce
cross-protective cellular responses capable of increasing the
level of immune control and inhibit spreading infection in
HIV-1-positive individuals. Thus, efforts to improve thecross-reactivity of env-specific vaccine might require the
creation of a polyvalent vaccine composed of env glyco-
proteins from multiple primary isolates or a vaccine in
which the structure of the env is modified to elicit cellular
and humoral responses to conserved epitopes that are
otherwise poorly immunogenic. Previously, we have dem-
onstrated that immunization of the HLA-A2/Kb transgenic
mice with the DV3 env mutant induced qualitative changes
at the level of env peptide-specific CD8+ T cell responses
that were associated with an increased recognition of target
cells expressing heterologous env gene products (Kiszka et
al., 2002). In these studies, we showed that the DV3 env
vaccine was not effective in eliciting neutralizing antibody
responses. These findings are consistent with previous
studies which demonstrated that immunization strategies
using variable loop-deleted env constructs failed to generate
cross-reactive neutralizing antibodies (Kim et al., 2003; Lu
et al., 1998). The experiments presented here also indicated
that partial deletions within the V3 loop in combination with
the V2-modified or V1/V2-deleted region were more effec-
tive in eliciting broader levels of cross-reactive CD8+ T cell
and neutralizing antibody responses than the single V3 loop-
deleted mutant or the WT gp14089.6 vaccine.
Using the challenge experiments with rVV-expressing
homologous or heterologous env gene products, we dem-
onstrated that modifications within the V3 domain that
increased the level of cross-reactive cellular responses in
vitro also elicited higher protection levels against challenge
with rVV expressing heterologous gp160 in the immunized
mice. Although immunization with the mV2 or the DV1/V2
mutant affected neither the level of cross-reactive CD8+ T
cell responses nor the protection against the heterologous
rVV challenge, adding mV3 into these constructs signifi-
cantly increased their immunogenic efficacies. Our findings
in the murine model together with the data available from
the HIV Molecular Database, which demonstrated the
presence of only three CTL epitopes with the HLA-A2-
and Cw8-binding motifs in the V1–V2 region (Korber et
al., 1999), indicate that this region might not be targeted by
CD8+ T cell responses. However, specific deletions within
the V1–V2 region could result in structural changes that
indirectly affected the immunogenicity of the mV2/mV3
and DV1/V2/mV3 mutants at the level of antigen processing
or presentation. Because the quantity of the epitope–MHC
complex on the cell surface may regulate CTL responses
(Yewdell and Bennink, 1992), it is possible that increases in
cross-reactive cellular responses induced by mV2/mV3 and
DV1/V2/mV3 vaccines could be associated with a higher
pool of conserved epitopes available for presentation in cells
expressing the double mutants than the WT env gene
products. This can be due to the appearance of new CTL
epitopes that are more frequently present on heterologous
envelopes than are those presented by unmodified gp14089.6
vaccine. Alternatively, the modified gp140 immunogen may
increase the relative concentration of conserved epitopes by
reducing a competition with less desirable epitopes during
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ies are required to determine the mechanism that contributes
to the increased immunogenicity of the conserved epitopes
in mV2/mV3 and DV1/V2/mV3 vaccines, results presented
here suggest that one possible approach to broaden the
repertoire of env-specific cellular responses is by modifica-
tions of the variable sequences within the env glycoprotein.
Consistent with the notion that both cellular and humoral
responses will be required for an effective AIDS vaccine,
understanding of the immunogenicity of env glycoproteins
from several primary HIV-1 isolates will be necessary for
the development of broadly protective immune responses.
Our results with the gp140 mutants of the HIV-189.6 isolate
demonstrated that despite different constrains for the induc-
tion of cross-reactive cellular and humoral responses, struc-
tural modifications of the env glycoprotein can be
introduced to redirect both types of immune responses
toward conserved epitopes that can be recognized on more
than one strain of HIV-1. It is also noteworthy that the
variable loop modifications had a more pronounced effect
on induction of cross-reactive cellular than neutralizing
antibody responses. This could be due to the inherent
difficulties of generating cross-neutralizing antibodies relat-
ed to the highly variable structure and glycosylation of
gp160 as well as the poor exposure and immunogenicity
of the receptor-biding sites on the env molecules (Kim et al.,
2003; Kwong et al., 1998; Wyatt et al., 1998). In addition,
the single immunization approach based on a DNA vaccine
that elicited low- to intermediate-avidity antibodies might
have reduced efficacy of the domain-modified vaccines. The
use of mouse sera in our assay and that of Kim et al. (2003),
which suffers from low neutralizing activities against pri-
mary isolates, could also contribute to the weak cross-
neutralizing responses induced by the variable domain-
deleted mutants. However, regardless of the differences in
the experimental models and HIV-1 isolates, in both systems
complete removal of the variable regions was not effective
in inducing cross-reactive cellular and antibody responses,
suggesting that partial deletions within these regions may
facilitate more effective approaches for boosting the breadth
of protective immunity.
In summary, we demonstrated that specific modifications
of the variable domains of the env glycoprotein could be
introduced with favorable antigenic properties. Additional
studies that would examine in detail the existence and
epitope-specificity of the cross-protective cellular and anti-
body responses elicited by mV2/mV3 and DV1/V2/mV3
gp14089.6 mutants may help to establish to what extent the
specific deletions differentially alter the structure of certain
env regions that are already immunogenic or render certain
regions immunogenic. Similarly, further studies with a panel
of heterologous primary isolates are also required to deter-
mine susceptibility of these HIV-1 isolates to neutralization
by antibodies elicited by mV2/mV3 and DV1/V2/mV3
gp14089.6 vaccines. These results will help to establish
whether the cross-reactive epitopes present on thosegp14089.6 mutants are absent from the heterologous isolates
that are resistant to neutralization or whether they are more
efficiently masked on these particular isolates than on the
viruses susceptible to neutralization. As such, this model
system will provide a comprehensive means for selecting
the most effective envelope vaccines for future vaccine
trials.Materials and methods
Vector construction
The HIV-189.6 gp140 plasmid (accession number
U39362) was used for the construction of env mutants
with complete or partially deleted V1/V2, V2, and V3
domains using a two-step PCR protocol using as described
(Kiszka et al., 2002). For each mutant, two fragments of
the env gene were synthesized with an overlap. One
fragment, with a specific deletion within the variable
domains, was synthesized with primer A containing the
KpnI cleavage site (5V-AATGGTACC TGTGTGGAGA-
GAAGCAACCAC-3V) together with anti-sense primer B
that contains overlapping sequences with primer C that
was used for synthesis of the second fragment (Table 4).
The second fragment was synthesized with sense primer C
in conjunction with the anti-sense primer D (5V-
CCTCCTGAGGATTGATTAAAGGCTATTGTT-3V) con-
taining the Bsu36I restriction site. The nucleotide sequen-
ces for the restriction enzyme cleavage sites are
underlined. These two fragments were then used together
in a second reaction along with primers A and D to
generate the indicated domain-modified env fragments.
The final product was digested with KpnI and Bsu36I
and exchanged with the corresponding segment of WT
gp14089.6 fused in frame with the tPA signal sequence
under the control of human cytomegalovirus immediate
early promoter in the pNGVL-7 plasmid (University of
Michigan, Ann Arbor, MI) as described (Kiszka et al.,
2002). Rev was not included in the gp140-expressing
plasmids as expression of env with the tPA signal se-
quence in pNGVL-7 allows env expression without Rev
(Lu et al., 1998). The integrity of the plasmid was verified
by restriction enzyme cleavage and DNA sequence analy-
sis. After DNA sequence verification, the expression of the
env gene products was confirmed by immunoprecipitation
from radiolabeled 293T cells transfected with the respec-
tive env-pNGVL-7 plasmid.
Transfection, labeling, and immunoprecipitation
Transient transfection of 293T cells was performed by
calcium phosphate precipitation with 50 Ag of plasmid
DNA encoding the respective env protein. For radioimmu-
noprecipitation analysis, [35S]methionine/cysteine (400 ACi
per plate; DuPont-New England Nuclear, Boston, MA)
Table 4
Nucleotide sequence of partially overlapping primers B and C used for generation of the variable domain-modified HIV-189.6 gp140 vaccines
V1/V2 and V3-modified Modified V1 and V2 domains Modified V3 domain
HIV-189.6 gp140
a
B C B C
WT N/A N/A N/A N/A
mV2 5V-TAACCTACCGGCACC
GATATAGAAAGAGCA-3V
5V-GGTGCCGTTAGGTTA
ATAAGTTGTAACACC-3V
N/A N/A
DV1/V2 5V-ACAGGCACCGGCACC
TACACATGGCTTTAG-3V
5V-GGTGCCGGTGCCT
GTCCAAAGGTATCC-3V
N/A N/A
mV3 N/A N/A 5V-TCTCCCTGGTCCTATA
GATAACCTTCTTCTTGC
ATTGTT-3V
5V-ATAGGACCAGGGAGA
GCATTTTATGCAAGATGT
AACATTAGTAGAGCA-3V
DV3 N/A N/A 5V-ACAATGGCCGGCACC
TGTACAATTAATTAC-3V
5V-GGTGCCGGCCATTGT
AACATTAGTAGAGCA-3V
mV2/mV3 5V-TAACCTACCGGCACC
GATATAGAAAGAGCA-3V
5V-GGTGCCGGTAGGTTA
ATAAGTTGTAACACC-3V
5V-TCTCCCTGGTCCTATA
GATAACCTTCTTCTTGC
ATTGTT-3V
5V-ATAGGACCAGGGAGA
GCATTTTATGCAAGATGT
AACATTAGTAGAGCA-3V
mV2/DV3 5V-TAACCTACCGGCACC
GATATAGAAAGAGCA-3V
5V-GGTGCCGTTAGGTTA
ATAAGTTGTAACACC-3V
5V-ACAATGGCCGGCACC
TGTACAATTAATTAC-3V
5V-GGTGCCGGCCATTGT
AACATTAGTAGAGCA-3V
DV1/V2/mV3 5V-ACAGGCACCGGCACC
TACACATGGCTTTAG-3V
5V-GGTGCCGGTGCCT
GTCCAAAGGTATCC-3V
5V-TCTCCCTGGTCCTATA
GATAACCTTCTTCTTGC
ATTGTT-3V
5V-ATAGGACCAGGGAGA
GCATTTTATGCAAGATGT
AACATTAGTAGAGCA-3V
DV1/V2/V3 5V-ACAGGCACCGGCACC
TACACATGGCTTTAG-3V
5V-GGTGCCGGTGCCT
GTCCAAAGGTATCC-3V
5V-ACAATGGCCGGCACC
TGTACAATTAATTAC-3V
5V-GGTGCCGGCCATTGT
AACATTAGTAGAGCA-3V
a The HIV-189.6 gp140 vaccines with complete or partially deleted V1, V2, and V3 regions were constructed using a two-step PCR method and partially
overlapping primers B and C as described in Materials and methods section.
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additional 12-h period. At the end of the incubation period,
the cells were pelleted and lysed using Nonidet P-40 buffer
(0.5% Nonidet P-40, 0.5 M NaCl, and 10 mM Tris–HCl,
[pH 7.5]). Equal amounts of radiolabeled cell lysates,
based on the protein concentration, were immunoprecipi-
tated with a mixture of sera from HIV-1-infected individ-
uals followed by polyclonal rabbit anti-human Ig (ICN
Biomedicals, Inc. Costa Mesa, CA) and protein A-Sephar-
ose CL-4B (Pharmacia Biotech, Piscataway, NJ). Immu-
noprecipitates were separated by sodium dodecyl sulfate-
8% polyacrylamide gel electrophoresis (SDS-PAGE). The
gels were fluorographed to visualize [35S]methionine/cys-
teine-labeled proteins, and the intensity of individual bands
was quantified with a LabImage Program (Copyright
1999–2001, Kapelan GmbH).
Flow cytometry analysis of the env glycoprotein expression
For intracellular staining of transfectants expressing the
WT and domain-modified env glycoproteins, 293T cells
were harvested 48 h after transfection, washed twice with
PBS containing 2% FCS and 0.1% sodium azide, and
stained with env-specific human mAbs 2F5 and 2G12
(Buchacher et al., 1994) (NIH AIDS Research and Refer-
ence Reagent Program, Rockville, MD). After washing, the
cells were incubated with a 1:40 dilution of FITC-conjugat-
ed F(abV)2 of goat anti-human Ig (ICN Biomedicals, Inc.)
and analyzed by flow cytometry (FACScan). The intracel-
lular staining was carried out using BD Cytofix/Cytoperm
kit (Pharmingen, San Diego, CA) according to the manu-
facturer’s protocol.Recombinant vaccinia viruses
The rVV’s expressing the full-length gp160 of HIV-1IIIB
(vPE16) (Earl et al., 1991) or h-galactosidase (vSC8) (Earl et
al., 1991) were provided by Dr. B. Moss (Laboratories of
Viral Diseases, National Institute of Allergy and Infectious
Diseases, Bethesda, MD). The rVV’s expressing the env
glycoprotein of the primary VI-06 (vV1) and 89.6 (vBD3)
HIV-1 isolates were provided by Drs. K. Luzuriaga (Univer-
sity ofMassachusettsMedical Center,Worcester,MA) and R.
Collman (University of Pennsylvania, Philadelphia, PA),
respectively. VI-06 is a ‘‘transmitted’’ primary isolate derived
from an infant with perinatal HIV-1 infection (Pikora et al.,
1997) that exhibits 8–10% sequence variation compared
with the env glycoprotein of the HIV-1IIIB isolate. The second
env glycoprotein derives from a dual-tropic HIV-189.6 prima-
ry isolate which uses CXCR4 and CCR5 as well as many
other chemokine co-receptors for entry (Doranz et al., 1996).
The HIV-189.6 isolate exhibits 82% identity with HIV-1IIIB
gp160 sequence with the highest (92%) and the lowest (64%)
sequence homology in the C1 region and the V3 loop,
respectively.
Mice and immunization
Six-week-old BALB/c (H-2d) mice were purchased from
the Jackson Laboratory (Bar Harbor,ME) andmaintained in a
specific pathogen-free microisolator environment. Mice were
injected i.m. in the quadriceps with 100 Ag of plasmid
encoding WT or domain-modified gp140 mutants on days
0, 14, 28, and 42. Control mice were immunized with a sham
plasmid. To augment the level of envelope-specific immune
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administered i.m. 2 days after immunization with the env-
specific vaccine as described (Barouch et al., 1998; Wierz-
bicki et al., 2002).
ELISPOT assay
The number of IFN-g-secreting Tcells specific for the env
gene products in splenocytes of the immunized mice was
determined by the ELISPOT method 3 weeks after the last
immunization as described (Gherardi and Esteban, 1999).
Briefly, 96-well nitrocellulose plates (Millipore multiscreen-
MAIP; Millipore, Bedford, MA) were coated with 15 Ag/ml
of rat anti-mouse mAb directed to IFN-g (MAB785, R and D
Systems Inc., Minneapolis, MN) in 0.05 M carbonate-bicar-
bonate buffer pH 9.6. After overnight incubation at 4 jC, the
wells were washedwith PBS containing 0.05%Tween 20 and
blocked for 1 h with RPMI 1640 medium containing 10%
FCS. For the analysis of frequencies of IFN-g-secreting cells
specific for the env gene products, splenocytes were com-
bined with target cells infected with vPE16, vBD3, vV1, or
vSC8 at a ratio of 3:1 and placed in 2-fold dilutions into the
antibody-coated wells. For each dilution duplicate samples
were used. P815 cells were used as antigen-presenting cells
(Gherardi and Esteban, 1999). After 24 h of incubation at 37
jC, the plates were washed six times with PBS containing
0.05% Tween 20 and incubated for 2 h with 50 Al of 1 Ag/ml
of biotinylated mAb directed to mouse IFN-g (MAB485,
R&D Systems Inc.). The plates were washed and incubated
for 1 h with 50 Al of 1:1000 diluted streptavidin-conju-
gated alkaline phosphatase (SA-5100, Vector Laboratories,
Burlingame, CA). After a final wash with PBS, spots were
developed with an alkaline phosphatase BCIP/NBT (5-
bromo-4-chloro-3-indolyl-1-phosphate/nitroblue tetrazoli-
um) substrate (SK-5400, Vector Laboratories) and counted
under a stereomicroscope. The frequencies of IFN-g-se-
creting cells were determined by regression analysis from a
curve generated by plotting the number of spots versus the
number of effector cells.
Protection against challenge with rVV expressing gp160
proteins of HIV-1 isolates
On day 28 after the last immunization with the env-
specific vaccines, mice were challenged i.p. with 5  106
PFU of vPE16, vBD3, vV1, or vSC8. Five days later, mice
were sacrificed, ovaries removed, homogenized, sonicated,
and assayed for vaccinia virus titer by plating serial 10-fold
dilutions on human HuTK 143B indicator cells, staining
with crystal violet and counting plaques at each dilution as
described (Kiszka et al., 2002).
Measurement of HIV-1 env-specific antibody endpoint titers
Serum samples from control or env-vaccine immunized
mice were analyzed for their reactivity to native viral envglycoprotein on vBD3-infected 293T cells in the ELISA
assay. Briefly, 293T cells (4  104 cells/well) cultured on
96-well plates were infected with vBD3 at a multiplicity of
infection of 10. After 12 h of infection, cells were fixed by
10-min treatment with 3.7% paraformaldehyde in PBS.
Following a wash with PBS containing 0.05% Tween 20
(PBS/Tween 20), the wells were blocked for 2 h with a
solution containing 2% BSA (Sigma) and 0.05% Tween 20
in PBS. Sera were prepared from murine blood samples,
serially diluted in PBS/Tween 20, and added to the wells.
For each dilution, duplicate wells were used. After 1-
h incubation at room temperature, the plates were washed
three times and incubated with a 1:500 dilution of a
peroxidase-conjugated goat anti-mouse Ig (IgG, IgM, and
IgA; Sigma) in PBS/Tween 20. After washing, the reaction
was developed with O-phenylenediamine (0.4 mg/ml; Sig-
ma) in 0.05 M phosphate-citrate buffer containing 0.03%
sodium perborate (Sigma), stopped with 0.4 N sulfuric acid,
and analyzed at 450 nm with an ELISA plate reader
(Dynatech MRX, Chantilly, VA). Sample dilutions were
considered positive if the optical density recorded for that
dilution was at least twofold higher than the optical density
recorded for a naive sample at the same dilution (Staats et
al., 1996).
Neutralizing antibody responses induced by the unmodified
and variable domain-modified env vaccines
The ability of env vaccines to generate neutralizing anti-
bodies was tested to determine which of these env mutants
could elicit a response to the functional env glycoprotein on
the homologous and heterologous HIV-1 viruses. The assay
was performed using the homologous HIV-189.6 isolate and
CEMx174 cells obtained from Dr. R. Collman (University of
Pennsylvania) or the heterologous HIV-1SF162 virus and
PHA-activated human peripheral blood mononuclear cells
(PBMC) as targets (Wierzbicki et al., 2002). The HIV-189.6
isolate exhibits 82% identity with HIV-1SF162 gp160 se-
quence with the highest (90%) and the lowest (62%) se-
quence homology in the C1 region and the V1 loop,
respectively.
The HIV-189.6 and HIV-1SF162 isolates were grown and
titrated in CEMx174 cells and in PHA-activated human
PBMC, respectively. The stocks were aliquoted and kept at
80 jC until further use. For antibody-mediated neutraliza-
tion, the virus stock diluted to one hundred 50% tissue culture
infectious doses (TCID50) in 50 Al of complete RPMI
medium was preincubated with an equal volume of heat-
inactivated (35 min at 56 jC) sera for 1 h at 37 jC in 96-well
tissue culture plates. For each sample, triplicate wells were
used. To account for the relatively high background and
variability frequently observed with mouse antisera, samples
were collected from control animals vaccinated with the sham
vector and served as controls for nonspecific neutralization.
To each well, 0.1 ml of medium containing 105 target cells
was added. Following 4-h incubation at 37 jC, half of the
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medium. Following centrifugation of the plate (5 min at 1500
rpm), half of the volume of each well was again replaced with
fresh medium. This procedure was repeated twice. The p24
antigen concentration in each well was evaluated 6 days after
infection by a p24-antigen-capture assay (NEN Life Science
Products, Inc., Boston, MA) according to the manufacturer’s
procedures. Each assay plate contained uninfected and
infected cell controls and a serum from an individual with
AIDS as a positive control (Kmieciak et al., 1998). Because
the infection was reduced in the presence of control sera, we
calculated the difference between the percent of inhibition
recorded with the immune sera minus that recorded with
control sera. The 1:20 serum dilution indicated in the text
refers to that present during the entire period of virus-cell
incubation.
Measurement of HIV-1 env-specific antibody avidity
The avidity index values of serum antibodies to the
native viral env were determined by measuring the resis-
tance of antibody–env glycoprotein complexes to an 8 M
urea wash in ConA ELISA (Cole et al., 1997). For avidity
assays, the ConA-anchored native viral env glycoprotein
substrate was purified from cell culture supernatants of
vBD3-infected 293T cells by Galanthus nivalis lectin affin-
ity column (Vector Laboratories) as described (Trkola et al.,
1996). For the ConA ELISA assay, all test sera were diluted
in 5% nonfat dry milk in PBS (BLOTTO) and plated in two
sets of duplicate wells. After the serum incubation, one set
of wells was treated in parallel for 5 min with either PBS or
a solution of 8 M urea in PBS. Following this treatment, the
wells were thoroughly washed with PBS and incubated with
a 1:500 dilution of a peroxidase-conjugated goat anti-mouse
Ig in PBS. After washing, the reaction was developed with
O-phenylenediamine (0.4 mg/ml; Sigma) in 0.05 M phos-
phate-citrate buffer containing 0.03% sodium perborate
(Sigma), stopped with 0.4 N sulfuric acid, and analyzed at
450 nm with an ELISA plate reader. The avidity index was
then calculated from the ratio of the absorbance value
obtained with urea treatment to that observed with PBS
treatment multiplied by 100. Antibodies with avidity index
values of V30% were designated low avidity, those with
index values between 30% and 50% were designated
intermediate avidity, and those with values z50% were
designated high avidity. While measurements of antibody
avidity were performed at the dilution producing an OD at
450 nm of about 1.0 in the endpoint titer ConA ELISA
procedure, experiments using several different dilutions
within this linear range were performed to ensure that the
variation in actual values was within 10%.
Data analysis
Amino acid sequences of gp160 proteins of primary HIV-
1 isolates were obtained through accession numbers avail-able from the HIV Sequence Database (http://hiv-web.
lanl.gov). The percentage of amino acid sequence identity
within immunogenic regions of gp160 proteins of primary
HIV-1 isolates was determined by the BLAST 2 program
(http://www.ncbi.nlm.nih.gov/BLAST). The numbering of
amino acids was based on the HxBc2 sequence available
from the HIV Sequence Database (http://hiv-web.lanl.gov)
using the HIV/SIV Sequence Locator Tool.
The significance of differences in the number of IFN-g-
secreting CD8+ cells specific for the env gene products and
the percentage of inhibition of HIV-1SF162 infection induced
by the full-length and domain-modified gp140 vaccines was
determined by the unpaired Student’s t test using JMP
software (SAS Institute Inc., Cary, NC). Mixed model
analysis of variance (Winer, 1971) was used to compare
mean values of the rVV titers between control mice and
those immunized with the unmodified and domain-modified
vaccines after challenge with vPE16, vBD3, vV1, or vSC8.Acknowledgments
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